CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery

Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days

NCT Number	NCT07687966
Lead Sponsor	Clarent Biopharma, Inc.
Conditions	Hip or Knee Replacement
Enrollment	80 participants
Start Date	2026-05-08
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-07